Abstract

Abstract Introduction Over the past several years there has been a rise in the number of clinics offering novel treatments for erectile dysfunction and Peyronie’s disease such as stem cell therapy, platelet rich plasma, and shockwave therapy Objective In this study, we attempt to identify to identify experimental treatment approaches for ED and PyD used by various clinics across the country. Methods Using a systematic search of online website directories, we identified 26 clinics were surveyed for PRP treatment, 27 for shockwave therapy, and 26 for stem cell therapy A standard questionnaire was used to retrieve information from all clinics regarding cost of treatment, duration of therapy, medical staff involved, and patient outcome data. Results We found that the cost of treatment varied widely between groups. PRP cost between $500 to $2400, Shockwave total cost was between $1500 - $7500, and stem cell therapy cost ranged between $3,800 to $16,000 USD. Across all clinics surveyed, a physician was involved in 67% of treatments and over 75% of clinics reported patient satisfaction following treatment. Conclusions Although the number of human clinical trials evaluating novel treatments for ED and PyD are limited, several clinics are offering these therapies with promises of success without evidence to support the claims. Our data demonstrates the wide use of experimental therapies for ED and PyD across the US. Clinical outcome data available for patients is largely up to the clinics discretion, and was only given to us in subjective measurements and testimonials. Disclosure No

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.